Annunziata Anna, Lanza Maurizia, Coppola Antonietta, Fiorentino Giuseppe
UOC Pathophysiology and Respiratory Rehabilitation, Intensive Care Department, Monaldi Hospital, Naples, Italy.
J Med Case Rep. 2021 May 10;15(1):231. doi: 10.1186/s13256-021-02847-w.
Generally, alpha-1 antitrypsin deficiency (AATD) is suspected in young patients with pulmonary emphysema or chronic obstructive pulmonary disease (COPD). Patients often suffer from diagnostic gaps and are misdiagnosed with chronic obstructive pulmonary disease (COPD), asthma, and airway hyperresponsiveness (AHR), as AATD may present with nonspecific respiratory symptoms. It is never too late to suspect AATD, especially in a patient with an unusual medical history. In recent years, evidence is beginning to emerge that there may be value in identifying and treating patients who do not already have deterioration of functional parameters.
We describe a case of a 69-year-old Caucasian female patient, late diagnosis of AATD, with both severe bronchial hyperreactivity and numerous exacerbations due to the peculiar clinical history and the presence of a rare mutation; although not presenting forced expiratory volume in 1 second (FEV) between 30 and 65%, the patient was treated with alpha-1 antitrypsin (AAT) augmentation therapy and achieved clinical and functional improvement.
AATD should always be suspected. The Alpha-1 Foundation recommendations for the diagnosis and management of AATD in adult patients indicate that treatment should be provided for patients with FEV between 30 and 65%. It may be useful to evaluate and treat patients based on clinical symptoms, even outside the established parameters, in particular cases.
一般来说,对于患有肺气肿或慢性阻塞性肺疾病(COPD)的年轻患者,会怀疑其患有α-1抗胰蛋白酶缺乏症(AATD)。由于AATD可能表现为非特异性呼吸道症状,患者常常存在诊断空白,被误诊为慢性阻塞性肺疾病(COPD)、哮喘和气道高反应性(AHR)。怀疑AATD永远都不晚,尤其是对于有不寻常病史的患者。近年来,越来越多的证据表明,识别和治疗尚未出现功能参数恶化的患者可能具有价值。
我们描述了一例69岁的白种女性患者,AATD诊断较晚,由于特殊的临床病史和罕见突变的存在,该患者同时患有严重的支气管高反应性且病情多次加重;尽管该患者一秒用力呼气容积(FEV)未在30%至65%之间,但接受了α-1抗胰蛋白酶(AAT)补充治疗并取得了临床和功能改善。
应始终怀疑AATD。成人患者AATD诊断和管理的α-1基金会建议指出,FEV在30%至65%之间的患者应接受治疗。在特定情况下,基于临床症状评估和治疗患者,即使超出既定参数范围,可能也是有用的。